Create a free Manufacturing.net account to continue

Royalty Pharma Increases Bid For Elan

Royalty Pharma is raising its offer to buy Elan on the condition that shareholders reject the Irish drugmaker's push to refocus its business through a string of recently announced deals. Royalty says it will pay $12.50 in cash for each share of Elan Corp. PLC. That adds up to a total value of about $7.5 billion.

NEW YORK (AP) -- Royalty Pharma is raising its offer to buy Elan on the condition that shareholders reject the Irish drugmaker's push to refocus its business through a string of recently announced deals.

Royalty says it will pay $12.50 in cash for each share of Elan Corp. PLC. That adds up to a total value of about $7.5 billion.

Royalty offered in February to buy Elan for $11 per share and later raised that bid to $11.25 per share.

Elan has said the $11.25 bid was much too low.

Royalty is a privately held New York company that buys royalty interests in drugs and late-stage drug candidates.

Elan plans to spend $1 billion for royalties from some respiratory treatments. It also plans to buy a privately held drugmaker and stakes in two others.

More in Supply Chain